文章：

血液恶性肿瘤免疫治疗中的新兴治疗靶点与耐药机制

Emerging Therapeutic Targets and Drug Resistance Mechanisms in Immunotherapy of Hematological Malignancies

原文发布日期：8 December 2023

DOI: 10.3390/cancers15245765

类型: Article

开放获取: 是

英文摘要：

CAR-T cell therapy has revolutionized the treatment of hematological malignancies with high remission rates in the case of ALL and NHL. This therapy has some limitations such as long manufacturing periods, persistent restricted cell sources and high costs. Moreover, combination regimens increase the risk of immune-related adverse events, so the identification new therapeutic targets is important to minimize the risk of toxicities and to guide more effective approaches. Cancer cells employ several mechanisms to evade immunosurveillance, which causes resistance to immunotherapy; therefore, a very important therapeutic approach is to focus on the development of rational combinations of targeted therapies with non-overlapping toxicities. Recent progress in the development of new inhibitory clusters of differentiation (CDs), signaling pathway molecules, checkpoint inhibitors, and immunosuppressive cell subsets and factors in the tumor microenvironment (TME) has significantly improved anticancer responses. Novel strategies regarding combination immunotherapies with CAR-T cells are the most promising approach to cure cancer.

摘要翻译： 

CAR-T细胞疗法已彻底改变血液系统恶性肿瘤的治疗格局，在急性淋巴细胞白血病和非霍奇金淋巴瘤中展现出高缓解率。然而该疗法存在生产周期长、细胞来源持续受限及成本高昂等局限性。联合治疗方案会增加免疫相关不良事件风险，因此识别新的治疗靶点对于降低毒性风险、指导更有效的治疗策略具有重要意义。癌细胞通过多种机制逃避免疫监视，导致免疫治疗耐药；因此，开发具有非重叠毒性的靶向治疗合理联合方案成为关键治疗策略。近期在分化簇抑制分子、信号通路分子、检查点抑制剂以及肿瘤微环境中免疫抑制细胞亚群与因子等领域的研究进展，显著提升了抗肿瘤应答效果。CAR-T细胞联合免疫治疗的新策略已成为治愈癌症最具前景的研究方向。

原文链接：

Emerging Therapeutic Targets and Drug Resistance Mechanisms in Immunotherapy of Hematological Malignancies